**Supplemental Table 2.** Adverse events (N=280)

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Mag-Roc** | **Sal-Succ** | **Total** |
|  |  |  |  |
| **Patients with at least one adverse event** | **15/141(11%)** | **39/139(28%)** | **54/280(19%)** |
|  |  |  |  |
| **Minor adverse events** |  |  |  |
| **Related to pretreatment (magnesium or saline)** |  |  |  |
| Nausea and/or retching | 3 | 0 | 3 |
| Skin rash | 1 | 0 | 1 |
| Pain at injection site | 1 | 0 | 1 |
| **Total (number and percentage of patients)** | **5/141 (4%)** | **0/139** | **5/280 (2%)** |
|  |  |  |  |
| **Related to injection of neuromuscular blocking agent** |
| Bronchospasm | 0 | 1 | 1 |
| Erythema | 4 | 11 | 15 |
| Edema | 0 | 0 | 0 |
| Hypotension | 1 | 1 | 2 |
| **Total (number and percentage of patients)** | **5/138a (4%)** | **13/137b (9%)** | **18/275 (7%)** |
|  |  |  |  |
| **At 24 h postoperative visit in patients who received study treatment** |
| Recall of intraoperative awareness | 0 | 0 | 0 |
| Postoperative muscle pain | 2 | 26 | 28 |
| **Total (number and percentage of patients)** | **2/138a (1%)** | **26/137b (19%)** | **28/275 (10%)** |
|  |  |  |  |
| **Other, unrelated to study treatment** |  |  |  |
| Ventricular extrasystole in PACU | 0 | 1 | 1 |
| Local hematoma at operation site | 1 | 0 | 1 |
| Postoperative hypovolemia | 0 | 1 | 1 |
| Postoperative hypoxemia (atelectasis) | 1 | 0 | 1 |
| Corneal lesion | 0 | 1 | 1 |
| Delayed awakening | 1 | 0 | 1 |
| Paresthesia on fingers | 0 | 1 | 1 |
| **Total (number and percentage of patients)** | **3/141 (2%)** | **4/139 (3%)** | **7/280 (3%)** |
|  |  |  |  |
| **Total of all minor adverse events** | **15** | **43** | **58** |
|  |  |  |  |
| **Serious adverse events** |  |  |  |
| Study drug application error | 0 | 1 | 1 |
| Postoperative hemorrhagic shock | 1 | 0 |  1 |
|  |  |  |  |
| **Total of all serious adverse events** | **1** | **1** | **2** |
|  |  |  |  |
| **Total of all adverse events** | **16** | **44** | **60** |

Mag-Roc = magnesium (pretreatment) +rocuronium; Sal-Succ = saline (pretreatment) + succinylcholine; PACU= post-anesthesia care unit.

aThree patients excluded before administration of the neuromuscular blocking agent due to adverse events occurring during the perfusion of the pretreatment.

bTwo patients excluded before administration of the neuromuscular blocking agent due to a damaged pretreatment bag and a study drug administration error (see serious adverse events).